Panoramica dell'azienda
DBV Technologies S.A. operates as a clinical-stage biopharmaceutical entity focused on the research and development of epicutaneous immunotherapy products, with its primary operations situated in France. The company functions within the Healthcare sector, specifically targeting the Biotechnology industry, where it aims to create novel treatments for allergic conditions. DBV Technologies S.A. currently holds a market capitalization of $1.27 billion, while generating an annual revenue of $5.64 million based on trailing twelve-month data. Although the number of employees is listed as N/A, the disparity between the substantial market cap and the modest revenue base of $5.64 million indicates that the market is pricing in significant future potential driven by its product pipeline, particularly Viaskin Peanut. This valuation suggests that investors are betting on the successful commercialization of its immunotherapy assets rather than current operational cash flows, as the company is still in the clinical trial phase for its key treatment of peanut allergy.
Salute finanziaria
The company reported a revenue of $5.64 million over the trailing twelve months, yet this income was offset by a net income of -$146,947,000 and an EBITDA of -$143,862,000. The substantial negative gap between the positive revenue of $5.64 million and the massive net loss reveals a cost structure dominated by high research and development expenditures typical of clinical-stage biotechnology firms. Free cash flow stands at -$64,285,000, which indicates that the company is consuming cash to fund its operations and clinical trials rather than generating liquidity from its current business activities. Despite the negative cash flow, the balance sheet retains $194.17 million in cash against a relatively low debt obligation of $6.53 million. The debt-to-equity ratio is recorded at 3.87, a figure that requires careful interpretation in the context of a pre-revenue biotech firm where equity dilution often accompanies high burn rates. The current ratio is 3.67, signaling robust short-term liquidity as current assets significantly exceed current liabilities. Return on Equity is -149.8% and Return on Assets is -61.4%, metrics that reflect the aggressive investment phase of the business where losses are expected to reduce equity and asset values while the company builds its asset base for future commercialization.
Valutazione del valore
The trailing P/E ratio is N/A due to the negative earnings, while the forward P/E is -81.03, implying that the market expects earnings to remain negative in the near term or that valuation models are relying on non-earnings based metrics. The price-to-book ratio is 5.98, indicating that the market values the company at nearly six times its book value, a significant premium often seen in biotechnology firms with valuable intellectual property portfolios. The price-to-sales ratio is 224.72, and the EV/EBITDA is -33.74, suggesting that traditional valuation multiples are distorted by the lack of profitability and that the stock price is heavily weighted toward future pipeline expectations. The 52-week high is $26.18 and the 52-week low is $6.69, placing the current trading price somewhere within this volatile range where the stock has experienced substantial movement. The beta is -0.20, a negative value that is anomalous for equities and suggests an inverse correlation with the broader market, meaning the stock may move counter to general market trends during periods of volatility.
Growth & Income
Revenue growth year-over-year is 26.2%, while earnings growth is N/A because the company has not yet achieved consistent profitability. The fact that revenue is growing while earnings remain negative implies that the company is scaling its top line through product development and clinical progress, but the costs associated with maintaining this growth, such as clinical trial expenses, are exceeding current revenues. DBV Technologies S.A. does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company retains all its earnings and cash reserves to reinvest into research and development rather than distributing income to shareholders. This reinvestment strategy is standard for clinical-stage biopharmaceutical companies that prioritize funding their pipeline, such as the Viaskin Peanut product, over providing immediate returns to investors. The overall growth and income profile is characterized by strong top-line expansion coupled with significant cash consumption and no current income distribution, reflecting a high-risk, high-reward investment thesis centered on future product approvals and market penetration.